Medscape

Expanded Pediatric Indication for Topical Roflumilast Under FDA Review

Roflumilast 0.05% (Zoryve), a topical phosphodiesterase-4 inhibitor, is currently approved for treating mild-to-moderate AD in children aged 2 years or older; it was approved for ...
CIDRAP

Paxlovid safe for children age 6 and up, new data reveal

A study finds that the antiviral drug is safe to prescribe in children with COVID-19 who are at least 6 years old.
The Manila Times

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 ...
The American Journal of Managed Care

Mechanism of Action: Treating patients with Mild to Moderate and Moderate to Severe Acne

A look at the most common medications used in patients with acne. Casey Butrus, PharmD: Hilary, we have many different treatment options for acne, different mechanisms of action that have been around ...
PregaTips on MSN

Dosage, signs, and what to watch

Oral Rehydration Solution works only when started at the right time and given in the correct amount. We’ll explain when to ...
Medscape

Mild-to-Moderate Kidney Injury Doesn't Worsen CKD

People with chronic kidney disease (CKD) and an episode of mild or moderate acute kidney injury (AKI) subsequently have a small nonsignificant incremental decline in kidney function, a finding that ...
The American Journal of Managed Care

Patients With Mild Psoriasis Face Less Favorable Status at Diagnosis, First Line of Treatment, Study Finds

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study. A recent poster ...